Levodopa–entacapone–carbidopa intestinal gel : Data from the Swedish national registry for Parkinson's disease
(2025) In European Journal of Neurology 32(1).- Abstract
Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range:... (More)
Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device-assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG-J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p-Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ-8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41). Conclusions: Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device-aided therapy for advanced PD. However, the long-term efficacy and tolerability of LECIG need to be further investigated.
(Less)
- author
- Öthman, Mezin
; Bergquist, Filip
; Odin, Per
LU
; Scharfenort, Monica LU ; Johansson, Anders ; Markaki, Ioanna ; Svenningsson, Per ; Dizdar, Nil and Nyholm, Dag LU
- organization
- publishing date
- 2025-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- levodopa, Parkinson's disease, registries, Sweden
- in
- European Journal of Neurology
- volume
- 32
- issue
- 1
- article number
- e16582
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:39625298
- scopus:85211161674
- ISSN
- 1351-5101
- DOI
- 10.1111/ene.16582
- language
- English
- LU publication?
- yes
- id
- 6657d0d1-adc2-48dd-93d0-5fc00f561517
- date added to LUP
- 2025-03-04 14:30:23
- date last changed
- 2025-04-29 18:47:05
@article{6657d0d1-adc2-48dd-93d0-5fc00f561517, abstract = {{<p>Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device-assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG-J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p-Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ-8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41). Conclusions: Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device-aided therapy for advanced PD. However, the long-term efficacy and tolerability of LECIG need to be further investigated.</p>}}, author = {{Öthman, Mezin and Bergquist, Filip and Odin, Per and Scharfenort, Monica and Johansson, Anders and Markaki, Ioanna and Svenningsson, Per and Dizdar, Nil and Nyholm, Dag}}, issn = {{1351-5101}}, keywords = {{levodopa; Parkinson's disease; registries; Sweden}}, language = {{eng}}, number = {{1}}, publisher = {{Wiley-Blackwell}}, series = {{European Journal of Neurology}}, title = {{Levodopa–entacapone–carbidopa intestinal gel : Data from the Swedish national registry for Parkinson's disease}}, url = {{http://dx.doi.org/10.1111/ene.16582}}, doi = {{10.1111/ene.16582}}, volume = {{32}}, year = {{2025}}, }